Here’s a breakdown of teh data provided, focusing on vaccine effectiveness and the number needed to vaccinate (NNV) for different outcomes and vaccine types in patients with cancer:
Monovalent Booster Effectiveness in Patients with cancer:
Preventing COVID-19 Related ICU Admission:
Overall for patients with cancer: 35.6% vaccine effectiveness.
NNV to prevent 1 ICU admission: 423 vaccinations.
For solid malignant neoplasms: NNV of 578 (95% CI,372-1939).
For hematologic malignant neoplasms: NNV of 252 (95% CI, 176-616).
Bivalent Booster Effectiveness in Patients with Cancer:
Preventing COVID-19 Hospitalization:
Overall for patients with cancer: 29.9% vaccine effectiveness.
NNV to prevent 1 COVID-19 hospitalization: 451 vaccinations.
Notable effectiveness in: patients with lung, breast, and urinary tract cancers, and those receiving cytotoxic chemotherapy, immunotherapy, or systemic corticosteroids. Preventing COVID-19 Related ICU Admission:
Overall for patients with cancer: 30.1% vaccine effectiveness (95% CI, 7.7%-47.0%).
NNV to prevent 1 ICU admission: 1805 people (95% CI,1154-7009).
Preventing Diagnosed COVID-19:
Overall for patients with cancer: 2.9% vaccine effectiveness (95% CI, -2.6% to 8.2%).
No effectiveness against diagnosed COVID-19 in: Those with solid or hematologic cancers.
Comparison of Bivalent Uptake:
Bivalent vaccine uptake was higher among patients with cancer (38%) than in nonimmunocompromised individuals (24%).
Key Takeaway from Authors:
Booster uptake was relatively low, and interventions are justified to increase COVID-19 vaccine uptake in this high-risk population.
Limitations of the Study:
Observational,retrospective design (risk of confounding and misclassification).
Incomplete vaccination records.
Site heterogeneity limiting generalizability.
Small sample sizes for some cancer subtypes.
Vaccination timing relative to treatment was not assessed.
* Underreported diagnoses due to at-home COVID-19 tests.
